Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Mount Sinai Medical Center, New York

Washington Cancer Institute at Medstar Washington Hospital Center, Washington D.C.

Greenbaum Cancer Center University of Maryland, Baltimore

Heinrich Heine Universität, Düsseldorf

Cleveland Clinic Foundation, Cleveland

Universitätsklinikum Köln, Cologne

Mayo Clinic, Rochester

The University of Chicago, Chicago

Hôpital Saint-Louis, Service d'Hématologie, Paris

The University of Texas MD Anderson Cancer Center, Houston

Anschutz Cancer Pavilion University of Colorado, Aurora

Stanford University School of Medicine, Stanford

Rutgers Cancer Institute of New Jersey, New Brunswick

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden